

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 February 2020 (06.02.2020)



(10) International Publication Number
WO 2020/025659 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) A61K 38/00 (2006.01)
C07K 14/47 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/EP2019/070596

(22) International Filing Date:

31 July 2019 (31.07.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

18186445.5 31 July 2018 (31.07.2018) EP
18204548.4 06 November 2018 (06.11.2018) EP

(71) Applicants: **PIERIS PHARMACEUTICALS GMBH**
[DE/DE]; Lise-Meitner-Strasse 30, 85354 Freising-Wei-
henstephan (DE). **LES LABORATOIRES SERVIER**
[FR/FR]; 35 rue de Verdun, 92284 Suresnes (FR).

(72) Inventors: **PAVLIDOU, Marina**; Katharina-Geisler-
Strasse 15, 85356 Freising (DE). **PATTARINI, Lucia**; 156
Rue de Tolbiac, 75013 Paris (FR). **SCHOLER-DAHIREL,**
Alix; 6 impasse du chemin de fer, 92000 Nanterre (FR).
ROTHER, Christine; Heinrich-Nicolaus-Strasse 26, 85221
Dachau (DE). **OLWILL, Shane**; Am Waldrand 29a, 84354
Freising (DE). **BEL AIBA, Rachida**; Erhardtstr. 15, 80469
Munich (DE). **HINNER, Marlon**; Eugen-Papst-Strasse 9,
81247 Munich (DE). **PEPER, Janet**; Skofja-Loka-Straße
7, 85354 Freising (DE).

(74) Agent: **SCHIWECK, Wolfram** et al.; c/o Schiweck
Weinzierl Koch, Patentanwälte, Ganghoferstrasse 68b,
80339 Munich (DE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))



WO 2020/025659 A1

(54) Title: NOVEL FUSION PROTEIN SPECIFIC FOR CD137 AND PD-L1

(57) Abstract: The disclosure provides fusion proteins specific for both CD 137 and PD-L1, which fusion protein can be used to co-stimulate lymphocyte activation in a PD-L1-target-dependent manner. Such fusion proteins can be used in many pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators for the treatment or prevention of human diseases such as a variety of tumors. The present disclosure also concerns methods of making the fusion proteins described herein as well as compositions comprising such fusion proteins. The present disclosure further relates to nucleic acid molecules encoding such fusion proteins and to methods for generation of such fusion proteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of such fusion proteins as well as compositions comprising one or more of such fusion proteins.